Patents Assigned to Inserm
  • Chimeric glycoproteins and pseudotyped lentiviral vectors
    Patent number: 8338168
    Abstract: The present invention provides improved chimeric glycoproteins (GPs) and improved lentiviral vectors pseudotyped with those glycoproteins. Also provided are methods and compositions for making such glycoproteins and vectors, and improved methods of in vitro and in vivo transduction of cells with such vectors. Improved chimeric GPs encode the extracellular and transmembrane domains of GALV or RD114 GPs fused to the cytoplasmic tail of MLV-A GP. Vectors pseudotyped with these GAL V/TR and RD 114/TR GP chimeras have significantly higher titers than vectors coated with the parental GPs. Additionally, RD114/TR-pseudotyped vectors are efficiently concentrated and are resistant to inactivation induced by the complement of both human and macaque sera. RD114 GP-pseudotyped lentiviral vectors have particular utility for in vivo gene transfer applications.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: December 25, 2012
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Clayton de la Recherche
    Inventors: Didier Trono, Francois-Loic Cosset, Virginie Sandrin, Bertrand Boson, Didier Negre, Patrick Salmon
  • Compounds having a potentiating effect on the activity of ethionamide and uses thereof
    Patent number: 8338599
    Abstract: The present invention relates to the use of compounds with a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, for the preparation of a medicament for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy, to pharmaceutical compositions comprising them in combination with an antibiotic that is activatable via the EthA pathway, to compounds having a potentiating effect on the activity of antibiotics that are activatable via the EthA enzymatic pathway, to pharmaceutical compositions comprising them and to their use as medicaments, especially medicaments for preventing and/or treating mycobacterial infections such as tuberculosis and leprosy.
    Type: Grant
    Filed: July 4, 2007
    Date of Patent: December 25, 2012
    Assignees: Institut Pasteur de Lille, Centre National de la Recherche Scientifique, Universite de Lille 2, Universite du Droit et de la Sante, Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Benoît Deprez, Nicolas Willand, Bertrand Dirie, Patrick Toto, Vincent Villeret, Camille Locht, Alain Baulard
  • Methods and kits for the diagnosis of rheumatoid arthritis
    Patent number: 8338188
    Abstract: The present invention relates to the identification and use of proteins with clinical relevance to rheumatoid arthritis (RA). In particular, the invention provides the identity of marker proteins that specifically react with RA-associated autoantibodies. Also provided are methods, arrays and kits for using these proteins in the diagnosis of RA, and in the selection and/or monitoring of treatment regimens.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: December 25, 2012
    Assignee: Inserm (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jean Roudier, Isabelle Auger
  • COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS
    Publication number: 20120321650
    Abstract: Epitopes derived from a protein present in an atherosclerotic plaque, such as apolipoprotein B-100, are presented. The epitopes can be used in a method of treating atherosclerosis by continuous subcutaneous or transcutaneous administration of a therapeutically effective amount of the epitope to a subject. Administering the epitope to the subject can induce a specific regulatory immune response, such as a Treg response. A composition or patch containing the epitope and adapted for the prophylactic or therapeutic treatment of a subject are also presented.
    Type: Application
    Filed: August 1, 2012
    Publication date: December 20, 2012
    Applicant: Institut National De La Sante Et De La Recherche Medicale (Inserm)
    Inventors: Alain TEDGUI, Ziad MALLAT
  • DIRECT PROTEIN DELIVERY WITH ENGINEERED MICROVESICLES
    Publication number: 20120322147
    Abstract: The present invention relates to direct protein delivery with engineered micro vesicles.
    Type: Application
    Filed: November 10, 2010
    Publication date: December 20, 2012
    Applicant: INSERM(institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Mangeot, Vincent Lotteau
  • Methods for increasing vascularization
    Patent number: 8329655
    Abstract: Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: December 11, 2012
    Assignees: Biogen Idec MA Inc., INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: Anthony Rossomando, Jean-Sebastien Silvestre, Radia Tamarat
  • Method for using HIP/PAP polypeptide composition for liver regeneration and prevention of liver failure
    Patent number: 8329661
    Abstract: This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytcs, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding that HIP/PAP administration has no adverse effects in mammals. This invention concerns a pharmaceutical composition for stimulating liver regeneration in vivo including after chronic/acute liver failure, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue (36) and ending at the amino acid residue (175) of sequence SEQ ID No 1, in combination with at least one physiologically acceptable excipient.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: December 11, 2012
    Assignees: Instiut National de la Santéet de la Recherche Médicale (INSERM), Universite Rene Descartes
    Inventors: Laurence Christa, Christian Brechot, Marie-Thérèse Simon-Gage-Soufflot, Alain Pauloin, J. Guilherme Tralhao
  • Composition for the treatment of atherosclerosis
    Patent number: 8324152
    Abstract: The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least one epitope to said subject induces a specific regulatory immune response, preferably a Treg response.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: December 4, 2012
    Assignee: Institute National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Alain Tedgui, Ziad Mallat
  • FKBP52-TAU INTERACTION AS A NOVEL THERAPEUTICAL TARGET FOR TREATING THE NEUROLOGICAL DISORDERS INVOLVING TAU DYSFUNCTION
    Publication number: 20120302595
    Abstract: The invention relates generally to neuro-protection and repair in neurological disorders involving Tau dysfunction (including Alzheimer's disease). The invention describes AND INCLUDES a direct interaction between proteins FKBP52 and Tau. More particularly, the invention relates to a method for screening a drug for the prevention and treatment of neurological disorders involving Tau dysfunction comprising the following steps: a) determining the ability of a candidate compound, to modulate the interaction between a Tau polypeptide and a FKBP52 polypeptide and b) selecting positively the candidate compound that modulates said interaction. The present invention finally relates to diagnostic, prognostic, and monitoring assays of neurological disorders involving Tau dysfunction.
    Type: Application
    Filed: September 24, 2010
    Publication date: November 29, 2012
    Applicant: INSERM
    Inventors: Etienne Baulieu, Beatrice Chambraud
  • COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS
    Publication number: 20120301465
    Abstract: Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.
    Type: Application
    Filed: March 26, 2012
    Publication date: November 29, 2012
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), BAYLOR RESEARCH INSTITUTE
    Inventors: Helene Dutartre, Yves Levy, Jacques F. Banchereau, Gerard Zurawski
  • Nucleic acids and polypeptides specific of the genus pathogenic strains
    Patent number: 8309100
    Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: November 13, 2012
    Assignees: Aventis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Luc Aujame, Annabelle Bouchardon, Geneviève Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnès Perrin
  • ENDOTHELIN INHIBITORS FOR THE TREATMENT OF RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS
    Publication number: 20120283190
    Abstract: The present invention relates to endothelin inhibitors for use in the treatment of Rapidly Progressive GlomeruloNephritis and to pharmaceutical compositions thereof.
    Type: Application
    Filed: December 8, 2010
    Publication date: November 8, 2012
    Applicant: Institut National De La Santé Et De La Recherche Medicale (INSERM)
    Inventors: Pierre-Louis Tharaux, Cecile Fligny
  • Method for treating skin wounds
    Patent number: 8303948
    Abstract: The present invention relates to a method for treating a skin wound in an individual, comprising applying to the skin wound of the individual a therapeutically effective quantity of gingival fibroblasts.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: November 6, 2012
    Assignees: Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale (INSERM), Assistance Publique—Hopitaux de Paris
    Inventors: Bruno Gogly, Bernard Coulomb, Antoine Lafont
  • Peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus
    Patent number: 8293528
    Abstract: The invention relates to peptide compositions for use in the preparation of pharmaceutical compositions against hepatitis C virus, as well as corresponding methods.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: October 23, 2012
    Assignees: Transgene SA, INSERM (Institut National de la Sante et de la Reserche Medicale)
    Inventors: Geneviève Inchauspe, Anne Fournillier, Nourredine Himoudi, Perrine Martin
  • COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
    Publication number: 20120264146
    Abstract: The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: -measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), -combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Application
    Filed: October 2, 2009
    Publication date: October 18, 2012
    Applicants: The Regents of the University of California, INSERM (Institut National de la sante et de la Recherche Medicale)
    Inventors: Ziad Mallat, Sotirios Tsimikas
  • METHOD FOR THE HYPOTHERMIC PERFUSION OF A CARDIAC ORGAN, AND DEVICE FOR THE IMPLEMENTATION THEREOF
    Publication number: 20120264104
    Abstract: The present invention relates to a method and device for the hypothermic perfusion of a cardiac organ. According to the invention, the infusion device comprises: a. a first sealed tank (2) that is capable of containing a physiological liquid (LP); b. a second sealed tank (3) that is in communication, in a sealed manner, with the inner space of the first tank by means of a nozzle (6); c. a means for refrigerating the first tank (2) and keeping it at a substantially constant temperature; and d. a means (4) for intermittently pressurizing the inner space of the first tank.
    Type: Application
    Filed: December 8, 2010
    Publication date: October 18, 2012
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET LA RECHER, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventor: René Ferrera
  • VLA-4 AS A BIOMARKER FOR PROGNOSIS AND TARGET FOR THERAPY IN DUCHENNE MUSCULAR DYSTROPHY
    Publication number: 20120258093
    Abstract: The invention relates to methods for the treatment of Duchenne muscular dystrophy and to methods for determining the prognosis of a subject affected with Duchenne Muscular Dystrophy. More particularly, the present invention relates to a VLA-4 antagonist for use in the treatment of Duchenne Muscular Dystrophy. The present invention also relates to a method for determining the prognosis of a subject affected with Duchenne Muscular Dystrophy wherein said method comprising a step consisting of determining the level of VLA-4 high T cells in a blood sample obtained from said subject.
    Type: Application
    Filed: August 19, 2010
    Publication date: October 11, 2012
    Applicant: Institut National De La Sante Et De La Recherche Medicale (INSERM)
    Inventors: Gillian Butler-Browne, Suse Dayse Silva-Barbosa, Wilson Savino, Alexandra Prufer De Queiroz Campos Araujo, Fernanda Pinto-Mariz, Luciana Rodrigues Carvalho, Thomas Voit
  • MITF AS A MARKER FOR PREDISPOSITION TO CANCER
    Publication number: 20120252904
    Abstract: The present invention relates to a mutant of MITF which is useful as a marker for predisposition to the development of cancer and to uses thereof in diagnosis and preventive treatments, sumoylation being reduced or absent in this mutant.
    Type: Application
    Filed: December 21, 2010
    Publication date: October 4, 2012
    Applicants: INSTITUT GUSTAVE ROUSSY, UNIVERSITE SOPHIA NICE ANTIPOLIS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE )
    Inventors: Robert Ballotti, Corine Bertolotto, Brigitte Bressac De Paillerets, Mahaut De Lichy, Fabienne Lesueur
  • Monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II)
    Patent number: 8278423
    Abstract: The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 2, 2012
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Isabelle Teulon, André Pelegrin
  • Neuronal Viability Factor and Use Thereof
    Publication number: 20120245093
    Abstract: This invention relates to methods and compositions for detection and treatment of neurodegenerative diseases. In particular, the invention relates to polypeptides that can protect against neuron degeneration, nucleic acid molecules that encode such polypeptides, and antibodies that recognize said polypeptides.
    Type: Application
    Filed: September 10, 2009
    Publication date: September 27, 2012
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Thierry Leveillard, Celine Jaillard, Jose-Alain Sahel